{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:03:07Z","timestamp":1765821787879,"version":"3.48.0"},"reference-count":19,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atypical Haemolytic Uremic Syndrome (aHUS) is a rare but life-threatening thrombotic microangiopathy. If inadequately managed, aHUS can lead to progressive kidney failure, cardiovascular complications and multiorgan dysfunction, resulting in high healthcare costs and a substantial impact on patients\u2019 quality of life. Novel complement inhibitors offer potential advantages, yet comprehensive evidence comparing their efficacy and safety is limited. This protocol elaborates the systematic review plans to evaluate the effectiveness and the drug safety of complement inhibitors in aHUS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search will be conducted across PubMed, Embase, Cochrane Library, Web of Science and Scopus to identify relevant studies. Eligible studies include randomised controlled trials (RCTs), observational studies and case series with at least three aHUS patients treated with novel complement inhibitors. Two independent reviewers will perform data extraction and quality assessment using standardised tools, including the Risk of Bias Tool 2 for RCTs and the Newcastle-Ottawa Scale for observational studies. A meta-analysis will be conducted if feasible, utilising a random-effects model to account for study heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval is not required as only previously published data will be used. Results will be disseminated via peer-reviewed journals and conferences, targeting healthcare professionals and policymakers to support evidence-based decision-making in aHUS management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42025629879.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100159","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T02:05:12Z","timestamp":1747274712000},"page":"e100159","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of novel complement inhibitors in atypical haemolytic uremic syndrome: a protocol for systematic review and meta-analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-7642","authenticated-orcid":false,"given":"Maulana","family":"Empitu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Airlangga University, Surabaya, East Java, Indonesia"},{"name":"Faculty of Health, Medicine, and Natural Sciences, Airlangga University, Banyuwangi, East Java, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruthvika","family":"Jayanthi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Airlangga University, Surabaya, East Java, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Nabhan","family":"Yasin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Airlangga University, Surabaya, East Java, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afaf","family":"Bouqoufi","sequence":"additional","affiliation":[{"name":"Ibn Zohr University, Agadir, Souss-Massa-Draa, Morocco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"2025121509594019000_15.5.e100159.1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/hematology.2024000543","article-title":"Atypical hemolytic uremic syndrome: diagnosis, management, and discontinuation of therapy","volume":"2024","author":"Java","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2025121509594019000_15.5.e100159.2","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.yapd.2014.04.001","article-title":"Atypical hemolytic uremic syndrome","volume":"61","author":"Greenbaum","year":"2014","journal-title":"Adv Pediatr"},{"key":"2025121509594019000_15.5.e100159.3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review","volume":"12","author":"Yan","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2025121509594019000_15.5.e100159.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2018.09.011"},{"key":"2025121509594019000_15.5.e100159.5","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.12.034"},{"key":"2025121509594019000_15.5.e100159.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981"},{"key":"2025121509594019000_15.5.e100159.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2019.07.016"},{"key":"2025121509594019000_15.5.e100159.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med"},{"key":"2025121509594019000_15.5.e100159.9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"2025121509594019000_15.5.e100159.10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12882-024-03638-3","article-title":"Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS- real-world data","volume":"25","author":"Sch\u00f6nfelder","year":"2024","journal-title":"BMC Nephrol"},{"key":"2025121509594019000_15.5.e100159.11","doi-asserted-by":"crossref","first-page":"103159","DOI":"10.1016\/j.eclinm.2025.103159","article-title":"Real-world use of complement inhibitors for haemolytic uraemic syndrome: an analysis of the European Rare Kidney Disease Registry cohort","volume":"82","author":"Vujovi\u0107","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2025121509594019000_15.5.e100159.12","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.2021012860","article-title":"Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond","volume":"139","author":"Gavriilaki","year":"2022","journal-title":"Blood"},{"key":"2025121509594019000_15.5.e100159.13","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ajh.27412","article-title":"Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition","volume":"99","author":"R\u00f6th","year":"2024","journal-title":"Am J Hematol"},{"key":"2025121509594019000_15.5.e100159.14","article-title":"Interventions for atypical haemolytic uraemic syndrome","volume":"3","author":"Pugh","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121509594019000_15.5.e100159.15","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2025121509594019000_15.5.e100159.16","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0259-8"},{"key":"2025121509594019000_15.5.e100159.17","unstructured":"Wells GA , Shea B , O\u2019Connell D , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000."},{"key":"2025121509594019000_15.5.e100159.18","unstructured":"Chandler J , Cumpston M , Li T , et al . Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley, 2019."},{"key":"2025121509594019000_15.5.e100159.19","doi-asserted-by":"publisher","DOI":"10.1111\/biom.13342"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T17:59:47Z","timestamp":1765821587000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,14]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/bmjopen-2025-100159"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100159","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}